Order now: BI-9553, a selective and well characterized non-nucleoside human cytomegalovirus DNA polymerase inhibitor
23 January 2023
Human cytomegalovirus (HCMV) belongs to the beta-herpes virus family and is among the largest of the DNA viruses. It encodes at least 208 proteins. HCMV can cause severe life-threatening infections especially in immunocompromised and immunonaive patients. CMV DNA polymerase is known to be one essential enzyme for viral replication. We are now glad to offer BI-9553, an HCMV DNA polymerase inhibitor, on opnMe.com, to foster novel research.
Inhibition of CMV polymerase enzymatic activity has been experimentally validated. BI-9553 is a potent (EC50 < 30 nM in a qPCR cell-based assay), selective, and well-characterized HCMV polymerase inhibitor that could be considered as a second-generation DNA polymerase inhibitor due to its unique structure. As a non-nucleoside, its cell activity could be dissociated from cytotoxicity depending on different cell lines. The molecule can be used for both in vitro and in vivo studies.
We invite you to investigate cytomegalovirus replication further and gain new insights into CMV biology with BI-9553 and its negative control BI-0309. The molecules will be shipped to you anywhere in the world for free. You will own all results you will generate with the molecules and may use them for your own publications.
No registration needed
Subscribe to our newsletter to stay updated as we add new molecules to opnMe.com.
About BI-9553:
BI-9553 is a potent (EC50 < 30 nM in a qPCR cell-based assay), selective, and well-characterized second-generation human cytomegalovirus (CMV) polymerase inhibitor. As a non-nucleoside, its cell activity could be dissociated from cytotoxicity depending on different cell lines. The molecule can be used for both in vitro and in vivo studies. Despite having high structural similarity to BI-9553, the negative control BI-0309 is inactive in biochemical and cellular assays, due to a substitution of a non-polar para-chlorine by a polar para-phenol group.
About opnMe:
opnMe.com, the new open innovation portal of Boehringer Ingelheim, aims to accelerate research initiatives to enable new insights of disease biology in areas of high unmet medical need by sharing well-characterized molecules and offer collaborations for science. In the spirit of collaboration, our molecules are provided to the scientific community to help unlock and fulfill their full potential. These molecules are either freely available as “Molecules to Order” or applied via scientific research submissions via our “Molecules for Collaboration” calls. As part of our third pillar, our “opn2EXPERTS” program, we also enlist scientific advice on key biologic issues to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs.